Collectively, this data demonstrate that interactions between cancer cells and mt-e-CAFs delay CC response to standard-of-care chemotherapy, and this is partly influenced by HSPG2 for mt-CCs but not for fl-CCs. This evidence concerns the gene HSPG2 and cancer.